Pulmonary eosinophilia associated to treatment with natalizumab
Natalizumab (Tysabri®) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who starte...
Main Authors: | Elena Curto, Elvira Munteis-Olivas, Eva Balcells, M Marisol Dominguez-Alvarez |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Annals of Thoracic Medicine |
Subjects: | |
Online Access: | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2016;volume=11;issue=3;spage=224;epage=226;aulast=Curto |
Similar Items
-
Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis
by: Marina Rodrigues Lima, et al.
Published: (2019-02-01) -
Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review
by: Yasuda Y, et al.
Published: (2019-11-01) -
Impact of natalizumab treatment on fatigue, mood and aspects of cognition in relapsing-remitting multiple sclerosis
by: Annett eKunkel, et al.
Published: (2015-05-01) -
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
by: Undine Proschmann, et al.
Published: (2021-04-01) -
The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study
by: Mehrdokht Mazdeh, et al.
Published: (2018-11-01)